KalshiVerifica disponibilitàKYC richiestoDati di risoluzione verificatiBen calibratoAvviso sulla qualità dei datiDati obsoleti
Dati al 31 ott 2026, 10:56 UTC · criterio pm-quality-4
Punto medio del book selezionato
Before Jan 1, 2029 · —
Caricamento del book selezionato…
—
Prezzo registrato
Before Jan 1, 2029 89.5%In testa tra 5 esiti
Before Jan 1, 2029 89.5%Qualità del mercato
65 / 100
Qualità mediaVolume 24h
612,8 €
Open interest
24,4K USD
Open interest medioBid / Ask
— / —
Before Jan 1, 2029Spread
—
Dati di mercato
Aggiornato 6 minuti fa
14 mag 26, 02:00 UTC1 gen 27, 04:59 UTC
Il grafico e le variazioni mostrano probabilità storiche salvate, non il book selezionato in tempo reale.
Trend
Riga selezionata: punto medio del book. Altre righe: riferimenti salvati, eventualmente normalizzati; le variazioni a 24h usano lo storico salvato.
Condizioni della piattaforma
Fonte: Kalshi
Queste condizioni sono informative; il trading simulato di CoinRithm segue regole proprie.
- Chiusura anticipata:
- Sì
- Tempo di liquidazione:
- 30m (indicativo)
Profondità di mercato · Before Jan 1, 2029
Caricamento del book selezionato…
—
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
When will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve a cure for Type 1 diabetes before 2033?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsRegole
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Si regola tramite:Food and Drug Administration
Regole per ogni esito
- Before Jan 1, 2029
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
